Literature DB >> 25258034

The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review.

David N Floyd1, Sue Langham, Hélène Chevrou Séverac, Barrett G Levesque.   

Abstract

BACKGROUND: Crohn's disease (CD) is associated with a substantial healthcare burden that affects the patient, healthcare systems and society in general. AIM: To provide a systematic evaluation of published data relating to the economic and health-related quality-of-life (HRQoL) burden of CD in selected European countries (Germany, France, UK, Italy, Spain) and the USA since 2000.
METHODS: We undertook a systematic review of publications relating to CD, its economic burden and impact on HRQoL. Research questions focused on the disease costs from a societal perspective and HRQoL burden in adults and pediatric/adolescent patients according to disease stage/severity. Total, direct and indirect costs were identified, as well as the impact of CD on HRQoL measured using both generic and disease-specific instruments.
RESULTS: Overall, 61 publications met the research criteria (38 on costs, 23 on HRQoL). CD in the USA and Europe together was associated with annual total costs of nearly <euro>30 billion, more than half due to indirect costs. HRQoL was consistently and statistically significantly lower among CD patients compared with normal populations, due to physical, emotional and social effects.
CONCLUSIONS: CD is a global health problem with high societal costs and substantial HRQoL burden. High-value care pathways including cost-effective therapies will help to induce and maintain remission, reduce complications of disease and improve HRQoL.

Entities:  

Mesh:

Year:  2014        PMID: 25258034     DOI: 10.1007/s10620-014-3368-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  47 in total

1.  Adjustment to inflammatory bowel disease: the relative influence of illness perceptions and coping.

Authors:  Angela Dorrian; Martin Dempster; Pauline Adair
Journal:  Inflamm Bowel Dis       Date:  2009-01       Impact factor: 5.325

2.  Hospitalized prevalence and 5-year mortality for IBD: record linkage study.

Authors:  Lori A Button; Stephen E Roberts; Michael J Goldacre; Ashley Akbari; Sarah E Rodgers; John G Williams
Journal:  World J Gastroenterol       Date:  2010-01-28       Impact factor: 5.742

Review 3.  Surgery for Crohn's disease in the era of biologicals: a reduced need or delayed verdict?

Authors:  Anthony de Buck van Overstraeten; Albert Wolthuis; André D'Hoore
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

4.  Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.

Authors:  Yifei Liu; Eric Q Wu; Arielle G Bensimon; Chun-Po Steve Fan; Yanjun Bao; Arijit Ganguli; Mei Yang; Mary Cifaldi; Parvez Mulani
Journal:  Adv Ther       Date:  2012-07-27       Impact factor: 3.845

5.  Assessment of long-term quality of life after laparoscopic and open surgery for Crohn's disease.

Authors:  K Thaler; A Dinnewitzer; M Oberwalder; E G Weiss; J J Nogueras; S D Wexner
Journal:  Colorectal Dis       Date:  2005-07       Impact factor: 3.788

Review 6.  Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life.

Authors:  Daniel Hommes; Jean-Frédéric Colombel; Paul Emery; Marco Greco; William J Sandborn
Journal:  J Crohns Colitis       Date:  2012-02       Impact factor: 9.071

7.  Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease.

Authors:  Heidi C Waters; Julie E Vanderpoel; Bijan Nejadnik; R Scott McKenzie; Orsolya E Lunacsek; Barbara J Lennert; John Goff; Damian H Augustyn
Journal:  J Med Econ       Date:  2011-10-24       Impact factor: 2.448

Review 8.  Management of active Crohn disease.

Authors:  Adam S Cheifetz
Journal:  JAMA       Date:  2013-05-22       Impact factor: 56.272

9.  Measuring quality of life in pediatric patients with inflammatory bowel disease: psychometric and clinical characteristics.

Authors:  James M Perrin; Karen Kuhlthau; Aziz Chughtai; Diane Romm; Barbara S Kirschner; George D Ferry; Stanley A Cohen; Benjamin D Gold; Melvin B Heyman; Robert N Baldassano; Harland S Winter
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-02       Impact factor: 2.839

10.  Health-related quality of life during natalizumab maintenance therapy for Crohn's disease.

Authors:  Brian G Feagan; William J Sandborn; Steven Hass; Timothy Niecko; Jeffrey White
Journal:  Am J Gastroenterol       Date:  2007-12       Impact factor: 10.864

View more
  39 in total

1.  Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.

Authors:  Steven J Edwards; Samantha Barton; Mariana Bacelar; Charlotta Karner; Peter Cain; Victoria Wakefield; Gemma Marceniuk
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

2.  The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases.

Authors:  G Conway; G Velonias; E Andrews; J J Garber; V Yajnik; A N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2017-01-20       Impact factor: 8.171

3.  The socio-economic impact of work disability due to inflammatory bowel disease in Brazil.

Authors:  Renata de S B Fróes; Ana Teresa Pugas Carvalho; Antonio Jose de V Carneiro; Adriana Maria Hilu de Barros Moreira; Jessica P L Moreira; Ronir R Luiz; Heitor S de Souza
Journal:  Eur J Health Econ       Date:  2017-05-18

4.  Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.

Authors:  Christopher V Almario; Michelle S Keller; Michelle Chen; Karen Lasch; Lyann Ursos; Julia Shklovskaya; Gil Y Melmed; Brennan M R Spiegel
Journal:  Am J Gastroenterol       Date:  2017-12-05       Impact factor: 10.864

5.  Cytokine refacing effect reduces granulocyte macrophage colony-stimulating factor susceptibility to antibody neutralization.

Authors:  Pete Heinzelman; Sharon J Carlson; George N Cox
Journal:  Protein Eng Des Sel       Date:  2015-04-07       Impact factor: 1.650

6.  Comparison of CT enterography and MR enterography imaging features of active Crohn disease in children and adolescents.

Authors:  Heather I Gale; Steven M Sharatz; Mayureewan Taphey; William F Bradley; Katherine Nimkin; Michael S Gee
Journal:  Pediatr Radiol       Date:  2017-05-03

7.  From clinical practice guideline development to trial registration: A systematic investigation of research pipeline for inflammatory bowel disease.

Authors:  Chase Meyer; Aaron Bowers; Trace E Heavener; Jake X Checketts; Matt Vassar
Journal:  Indian J Gastroenterol       Date:  2019-07-03

Review 8.  Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Opin Investig Drugs       Date:  2016       Impact factor: 6.206

9.  Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.

Authors:  Remo Panaccione; A Hillary Steinhart; Brian Bressler; Reena Khanna; John K Marshall; Laura Targownik; Waqqas Afif; Alain Bitton; Mark Borgaonkar; Usha Chauhan; Brendan Halloran; Jennifer Jones; Erin Kennedy; Grigorios I Leontiadis; Edward V Loftus; Jonathan Meddings; Paul Moayyedi; Sanjay Murthy; Sophie Plamondon; Greg Rosenfeld; David Schwartz; Cynthia H Seow; Chadwick Williams; Charles N Bernstein
Journal:  J Can Assoc Gastroenterol       Date:  2018-07-10

10.  Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.

Authors:  Petra Baji; László Gulácsi; Valentin Brodszky; Zsuzsanna Végh; Silvio Danese; Peter M Irving; Laurent Peyrin-Biroulet; Stefan Schreiber; Fanni Rencz; Péter L Lakatos; Márta Péntek
Journal:  United European Gastroenterol J       Date:  2017-05-08       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.